NASDAQ:ZYNE - Zynerba Pharmaceuticals Stock Price, Price Target & More

$10.56 +0.25 (+2.42 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$10.56
Today's Range$10.01 - $10.64
52-Week Range$5.42 - $24.57
Volume202,431 shs
Average Volume323,054 shs
Market Capitalization$135.07 million
P/E Ratio-4.26
Dividend YieldN/A
Beta4.94

About Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZYNE
CUSIPN/A
Phone484-581-7505

Debt

Debt-to-Equity RatioN/A
Current Ratio9.17%
Quick Ratio9.17%

Price-To-Earnings

Trailing P/E Ratio-4.26
Forward P/E Ratio-4.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales14,319.36
Cash FlowN/A
Price / CashN/A
Book Value$4.50 per share
Price / Book2.35

Profitability

EPS (Most Recent Fiscal Year)($2.48)
Net Income$-32,010,000.00
Net MarginsN/A
Return on Equity-46.64%
Return on Assets-41.86%

Miscellaneous

Employees22
Outstanding Shares13,560,000

How to Become a New Pot Stock Millionaire

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced its quarterly earnings data on Monday, March, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.60). During the same period last year, the firm earned ($0.71) earnings per share. View Zynerba Pharmaceuticals' Earnings History.

What price target have analysts set for ZYNE?

11 equities research analysts have issued 1-year price objectives for Zynerba Pharmaceuticals' stock. Their forecasts range from $7.00 to $32.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $18.45 in the next twelve months. View Analyst Ratings for Zynerba Pharmaceuticals.

What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (3/15/2018)
  • 2. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)
  • 3. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)

Who are some of Zynerba Pharmaceuticals' key competitors?

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the folowing people:
  • Mr. Armando Anido MBA, Chairman and Chief Exec. Officer (Age 60)
  • Ms. Terri B. Sebree, Pres (Age 60)
  • Mr. James E. Fickenscher, Chief Financial Officer and VP of Corp. Devel. (Age 54)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 49)
  • Ms. Suzanne M. Hanlon, VP of HR, Gen. Counsel and Sec. (Age 61)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Has Zynerba Pharmaceuticals been receiving favorable news coverage?

News articles about ZYNE stock have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also gave media coverage about the company an impact score of 47.44 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $10.56.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $135.07 million and generates $10,000.00 in revenue each year. The company earns $-32,010,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Zynerba Pharmaceuticals employs 22 workers across the globe.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]


MarketBeat Community Rating for Zynerba Pharmaceuticals (ZYNE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Zynerba Pharmaceuticals in the last 12 months. Their average twelve-month price target is $18.45, suggesting that the stock has a possible upside of 74.72%. The high price target for ZYNE is $32.00 and the low price target for ZYNE is $7.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.642.642.442.44
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.45$18.45$15.50$14.6250
Price Target Upside: 74.72% upside83.40% upside15.16% upside65.82% upside

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Consensus Price Target History

Price Target History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018HC WainwrightSet Price TargetBuy$23.00MediumView Rating Details
3/13/2018Seaport Global SecuritiesReiterated RatingBuyLowView Rating Details
3/13/2018OppenheimerReiterated RatingHoldMediumView Rating Details
3/12/2018Cantor FitzgeraldSet Price TargetBuy$20.00MediumView Rating Details
1/29/2018Ladenburg ThalmannInitiated CoverageBuy -> Buy$25.50HighView Rating Details
12/4/2017Canaccord GenuitySet Price TargetOutperform -> Buy$15.00 -> $18.00HighView Rating Details
11/14/2017Piper JaffrayBoost Price Target$16.00 -> $20.00N/AView Rating Details
10/1/2017Roth CapitalSet Price TargetBuy$15.00MediumView Rating Details
8/15/2017CIBCReiterated RatingOutperform -> Market PerformLowView Rating Details
8/15/2017Jefferies GroupDowngradeBuy -> Hold$12.00 -> $7.00LowView Rating Details
8/14/2017Maxim GroupReiterated RatingHoldHighView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings History and Estimates Chart

Earnings by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings Estimates

2018 EPS Consensus Estimate: ($2.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.65)($0.62)($0.63)
Q2 20183($0.70)($0.61)($0.64)
Q3 20183($0.79)($0.54)($0.65)
Q4 20183($0.85)($0.52)($0.67)

Zynerba Pharmaceuticals (NASDAQ ZYNE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018Q4 2017($0.60)($0.60)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.5850)($0.6340)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.60)($0.64)$0.38 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.5460)($0.60)$0.07 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.75)($0.71)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.69)($0.67)$0.20 millionViewN/AView Earnings Details
8/11/2016Q2($0.5250)($0.70)$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)$0.03 million$0.01 millionViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)$0.20 million$0.05 millionViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)$0.20 millionViewN/AView Earnings Details
8/27/2015Q2 2015($0.80)$0.02 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Zynerba Pharmaceuticals (NASDAQ ZYNE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.91%
Institutional Ownership Percentage: 28.93%
Insider Trading History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals (NASDAQ ZYNE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2018Michael RappMajor ShareholderBuy10,000$9.28$92,800.00View SEC Filing  
1/2/2018Michael RappMajor ShareholderBuy15,000$12.99$194,850.00View SEC Filing  
10/23/2017Michael RappMajor ShareholderBuy25,745$9.94$255,905.30View SEC Filing  
10/19/2017Michael RappMajor ShareholderBuy44,255$9.59$424,405.45View SEC Filing  
5/15/2017Armando AnidoChairmanBuy5,000$19.70$98,500.00336,012View SEC Filing  
5/12/2017James E FickenscherCFOBuy5,200$19.82$103,064.0012,200View SEC Filing  
12/29/2016Michael RappMajor ShareholderBuy10,000$15.85$158,500.001,354,115View SEC Filing  
12/7/2016James E FickenscherCFOBuy7,000$14.08$98,560.003,000View SEC Filing  
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.0039,893View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zynerba Pharmaceuticals (NASDAQ ZYNE) News Headlines

Source:
DateHeadline
Maxim Group Analysts Give Zynerba Pharmaceuticals (ZYNE) a $32.00 Price TargetMaxim Group Analysts Give Zynerba Pharmaceuticals (ZYNE) a $32.00 Price Target
www.americanbankingnews.com - April 20 at 1:54 PM
HC Wainwright Reiterates "$23.00" Price Target for Zynerba Pharmaceuticals (ZYNE)HC Wainwright Reiterates "$23.00" Price Target for Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - April 16 at 8:17 AM
Zynerba Pharmaceuticals Appoints John P. Butler to Board of DirectorsZynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
feeds.benzinga.com - April 16 at 7:46 AM
Can Cannabis Treat Seizures? Biotechs Say The Answer Is YesCan Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
finance.yahoo.com - April 13 at 5:23 PM
HC Wainwright Lowers Zynerba Pharmaceuticals (ZYNE) to NeutralHC Wainwright Lowers Zynerba Pharmaceuticals (ZYNE) to Neutral
www.americanbankingnews.com - April 12 at 9:00 PM
Zynerba Pharmaceuticals initiates Phase 2 trial of ZYN002 in DEEZynerba Pharmaceuticals initiates Phase 2 trial of ZYN002 in DEE
seekingalpha.com - April 10 at 5:22 PM
Oppenheimer Downgrades Zynerba Pharmaceuticals (ZYNE) to Market PerformOppenheimer Downgrades Zynerba Pharmaceuticals (ZYNE) to Market Perform
www.americanbankingnews.com - April 10 at 11:28 AM
BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)
www.reuters.com - April 10 at 8:40 AM
Zynerba Pharma (ZYNE) Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic EncephalopathiesZynerba Pharma (ZYNE) Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies
www.streetinsider.com - April 10 at 8:40 AM
Zacks: Brokerages Anticipate Zynerba Pharmaceuticals (ZYNE) Will Post Earnings of -$0.64 Per ShareZacks: Brokerages Anticipate Zynerba Pharmaceuticals (ZYNE) Will Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 10 at 3:13 AM
Zynerba Pharmaceuticals (ZYNE) Stock Rating Upgraded by Cantor FitzgeraldZynerba Pharmaceuticals (ZYNE) Stock Rating Upgraded by Cantor Fitzgerald
www.americanbankingnews.com - April 8 at 3:17 PM
Zynerba Pharmaceuticals (ZYNE) Given Consensus Recommendation of "Buy" by BrokeragesZynerba Pharmaceuticals (ZYNE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 1:47 PM
Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98?Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98?
finance.yahoo.com - April 3 at 5:25 PM
Zynerba Pharmaceuticals (ZYNE) Cut to "Strong Sell" at ValuEngineZynerba Pharmaceuticals (ZYNE) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM
Zynerba Pharmaceuticals (ZYNE) Given a $17.00 Price Target at Cantor FitzgeraldZynerba Pharmaceuticals (ZYNE) Given a $17.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 5:08 PM
Zynerba Pharmaceuticals (ZYNE) Given Hold Rating at OppenheimerZynerba Pharmaceuticals (ZYNE) Given Hold Rating at Oppenheimer
www.americanbankingnews.com - March 30 at 5:08 PM
Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating ...Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating ...
globenewswire.com - March 28 at 8:40 AM
Zynerba Pharma (ZYNE) Announces Publication of Preclinical Data in NeuropsychopharmacologyZynerba Pharma (ZYNE) Announces Publication of Preclinical Data in Neuropsychopharmacology
www.streetinsider.com - March 26 at 5:09 PM
Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction ModelZynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model
finance.yahoo.com - March 26 at 8:33 AM
 Analysts Expect Zynerba Pharmaceuticals Inc (ZYNE) to Announce -$0.65 EPS Analysts Expect Zynerba Pharmaceuticals Inc (ZYNE) to Announce -$0.65 EPS
www.americanbankingnews.com - March 24 at 1:12 AM
Insider Buying: Zynerba Pharmaceuticals Inc (ZYNE) Major Shareholder Buys 10,000 Shares of StockInsider Buying: Zynerba Pharmaceuticals Inc (ZYNE) Major Shareholder Buys 10,000 Shares of Stock
www.americanbankingnews.com - March 23 at 10:35 AM
Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of ... - GlobeNewswire (press release)Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of ... - GlobeNewswire (press release)
globenewswire.com - March 23 at 8:31 AM
Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
finance.yahoo.com - March 22 at 8:38 AM
Zynerba Pharmaceuticals (ZYNE) PT Set at $20.00 by Cantor FitzgeraldZynerba Pharmaceuticals (ZYNE) PT Set at $20.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 18 at 12:26 PM
Zynerba Pharmaceuticals (ZYNE) Given a $23.00 Price Target by HC Wainwright AnalystsZynerba Pharmaceuticals (ZYNE) Given a $23.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 18 at 10:24 AM
Oppenheimer Reiterates "Hold" Rating for Zynerba Pharmaceuticals (ZYNE)Oppenheimer Reiterates "Hold" Rating for Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - March 17 at 9:24 PM
FY2018 EPS Estimates for Zynerba Pharmaceuticals Inc Decreased by Analyst (ZYNE)FY2018 EPS Estimates for Zynerba Pharmaceuticals Inc Decreased by Analyst (ZYNE)
www.americanbankingnews.com - March 16 at 10:04 AM
Zynerba Pharmaceuticals Inc to Post Q2 2018 Earnings of ($0.70) Per Share, Oppenheimer Forecasts (ZYNE)Zynerba Pharmaceuticals Inc to Post Q2 2018 Earnings of ($0.70) Per Share, Oppenheimer Forecasts (ZYNE)
www.americanbankingnews.com - March 16 at 8:52 AM
Zynerba Pharmaceuticals Inc Forecasted to Post Q2 2018 Earnings of ($0.61) Per Share (ZYNE)Zynerba Pharmaceuticals Inc Forecasted to Post Q2 2018 Earnings of ($0.61) Per Share (ZYNE)
www.americanbankingnews.com - March 16 at 8:50 AM
Analysts Expect Breakeven For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)Analysts Expect Breakeven For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)
finance.yahoo.com - March 16 at 8:30 AM
Zynerba Pharmaceuticals (ZYNE) Lifted to "Buy" at Zacks Investment ResearchZynerba Pharmaceuticals (ZYNE) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 15 at 12:50 PM
Seaport Global Securities Reaffirms "Buy" Rating for Zynerba Pharmaceuticals (ZYNE)Seaport Global Securities Reaffirms "Buy" Rating for Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - March 15 at 10:02 AM
Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference - GlobeNewswire (press release)Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:28 AM
Jefferies Group Equities Analysts Boost Earnings Estimates for Zynerba Pharmaceuticals Inc (ZYNE)Jefferies Group Equities Analysts Boost Earnings Estimates for Zynerba Pharmaceuticals Inc (ZYNE)
www.americanbankingnews.com - March 15 at 6:38 AM
Research Analysts Set Expectations for Zynerba Pharmaceuticals Incs Q1 2018 Earnings (ZYNE)Research Analysts Set Expectations for Zynerba Pharmaceuticals Inc's Q1 2018 Earnings (ZYNE)
www.americanbankingnews.com - March 15 at 6:38 AM
Equities Analysts Issue Forecasts for Zynerba Pharmaceuticals Incs Q1 2018 Earnings (ZYNE)Equities Analysts Issue Forecasts for Zynerba Pharmaceuticals Inc's Q1 2018 Earnings (ZYNE)
www.americanbankingnews.com - March 15 at 6:38 AM
Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare ConferenceZynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 6:53 PM
Jefferies Group Weighs in on Zynerba Pharmaceuticals Incs FY2022 Earnings (ZYNE)Jefferies Group Weighs in on Zynerba Pharmaceuticals Inc's FY2022 Earnings (ZYNE)
www.americanbankingnews.com - March 14 at 4:22 PM
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:49 AM
Zynerba Pharmaceuticals (ZYNE) Posts  Earnings ResultsZynerba Pharmaceuticals (ZYNE) Posts Earnings Results
www.americanbankingnews.com - March 13 at 10:56 AM
Today’s Research Reports on Trending Tickers: Kura Oncology and Zynerba PharmaceuticalsToday’s Research Reports on Trending Tickers: Kura Oncology and Zynerba Pharmaceuticals
finance.yahoo.com - March 13 at 8:37 AM
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights
finance.yahoo.com - March 12 at 10:27 AM
Zynerba Pharmaceuticals Inc (ZYNE) Given Consensus Recommendation of "Hold" by AnalystsZynerba Pharmaceuticals Inc (ZYNE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 10 at 1:53 PM
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This WeekPot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
feeds.benzinga.com - March 9 at 5:14 PM
Wired News – Zynerba Pharma Held Positive Discussion Meeting with FDA for its ZYN002 Development StrategyWired News – Zynerba Pharma Held Positive Discussion Meeting with FDA for its ZYN002 Development Strategy
finance.yahoo.com - March 7 at 6:23 PM
Zynerba Pharmaceuticals Inc (ZYNE) Expected to Post Earnings of -$0.61 Per ShareZynerba Pharmaceuticals Inc (ZYNE) Expected to Post Earnings of -$0.61 Per Share
www.americanbankingnews.com - March 6 at 9:22 PM
Main Line pharma company plans key study of Fragile X syndrome therapyMain Line pharma company plans key study of Fragile X syndrome therapy
finance.yahoo.com - March 5 at 5:43 PM
Cantor Fitzgerald Initiates Coverage on Zynerba Pharmaceuticals (ZYNE)Cantor Fitzgerald Initiates Coverage on Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - March 5 at 2:58 PM
Zynerba (ZYNE) Announces Positive Meeting with FDA and Plans to Conduct Single Pivotal Study of ZYN002 in Fragile ... - StreetInsider.comZynerba (ZYNE) Announces Positive Meeting with FDA and Plans to Conduct Single Pivotal Study of ZYN002 in Fragile ... - StreetInsider.com
www.streetinsider.com - March 5 at 8:31 AM
Zynerba Pharmaceuticals Announces Positive Meeting with US Food and Drug Administration and Plans to Conduct a ... - GlobeNewswire (press release)Zynerba Pharmaceuticals Announces Positive Meeting with US Food and Drug Administration and Plans to Conduct a ... - GlobeNewswire (press release)
globenewswire.com - March 5 at 8:31 AM

SEC Filings

Zynerba Pharmaceuticals (NASDAQ:ZYNE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zynerba Pharmaceuticals (NASDAQ ZYNE) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.